SCHEMBL144526

SCHEMBL144526

C[C@@]1(n2cnc3c(O)ncnc32)O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNPH1 O43598 6/20 0.46
P2RY1 P47900 2/20 0.46
TAS1R3 Q7RTX0 2/20 0.46
TAS1R1 Q7RTX1 2/20 0.46
PRKAB2 O43741 1/20 0.46
TRPM2 O94759 1/20 0.46
LDHA P00338 1/20 0.46
ADRB2 P07550 1/20 0.46
FBP1 P09467 1/20 0.46
SRC P12931 1/20 0.46
ADORA1 P30542 1/20 0.46
P2RY2 P41231 1/20 0.46
PRKAG1 P54619 1/20 0.46
PRKAA2 P54646 1/20 0.46
PDE4D Q08499 1/20 0.46
KCNH2 Q12809 1/20 0.46
PRKAA1 Q13131 1/20 0.46
PDE3A Q14432 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
P2RY11 Q96G91 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29465207 1.00 DNPH1 (0.46) DNPH1P2RY1TAS1R3TAS1R1PRKAB2
SCHEMBL8441747 0.91 P2RX3 (0.53) P2RY1SRCP2RY2SMN1; SMN2P2RX1
SCHEMBL16108838 0.89 P2RY1 (0.59) DNPH1P2RY1TAS1R3TAS1R1PRKAB2
SCHEMBL3859625 0.89 DNPH1 (0.45) DNPH1P2RY1TAS1R3TAS1R1PRKAB2
SCHEMBL16700549 0.88 P2RY1 (0.58) DNPH1P2RY1TAS1R3TAS1R1PRKAB2
Phosphoric Acid SCHEMBL635802 0.86 PI4KA (0.40) ADORA1SMN1; SMN2
SCHEMBL3218602 0.86 DNPH1 (0.44) DNPH1P2RY1TAS1R3TAS1R1PRKAB2
SCHEMBL5801879 0.86 DNPH1 (0.44) DNPH1P2RY1TAS1R3TAS1R1PRKAB2
SCHEMBL17515130 0.85 DNPH1 (0.45) DNPH1P2RY1TAS1R3TAS1R1PRKAB2
SCHEMBL41364 0.82 PI4KA (0.43) ADORA1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 619 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8268352-B2 Modified release composition for highly soluble drugs TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-18 US claimed
US-8263125-B2 Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-11 US claimed
CN-100558407-C Preparation contains the clear aqueous solution dosage form of bile acid YOO SEO HONG (US) 2009-11-11 CN claimed
EP-1624894-A4 METHODS AND COMPOSITIONS FOR MATURING DENDRITIC CELLS UTILIZING INOSINE-CONTAINING COMPOUNDS IRX THERAPEUTICS INC (US) 2009-08-26 EP claimed
CN-101048164-A Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis YOO SEO HONG (US) 2007-10-03 CN claimed
EP-1819318-A1 DRIED FORMS OF AQUEOUS SOLUBILIZED BILE ACID DOSAGE FORMULATION Yoo, Seo Hong (US) 2007-08-22 EP claimed
EP-1814558-A2 METHODS AND COMPOSITIONS FOR REDUCING NEURODEGENERATION IN AMYOTROPHIC LATERAL SCLEROSIS Yoo, Seo Hong (US) 2007-08-08 EP claimed
US-20070082863-A1 Methods and compositions for maturing dendritic cells utilizing inosine-containing compounds IRX THERAPEUTICS, INC. 2007-04-12 US claimed
US-7166299-B2 Preparation of aqueous clear solution dosage forms with bile acids YOO SEO HONG 2007-01-23 US claimed
US-20060142241-A1 Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis YOO SEO H 2006-06-29 US claimed
US-20050158408-A1 Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof YOO SEO H (US) 2005-07-21 US claimed
US-20050148538-A1 Adjuvant formulations for bacterial and virus vaccines and method of making same IRX THERAPEUTICS, INC. 2005-07-07 US claimed
WO-2005003295-A2 METHODS AND COMPOSITIONS FOR MATURING DENDRITIC CELLS UTILIZING INOSINE-CONTAINING COMPOUNDS IRX THERAPEUTICS, INC. (US) 2005-01-13 WO claimed
EP-1465639-A2 ADJUVANT FORMULATIONS FOR BACTERIAL AND VIRUS VACCINES AND METHOD OF MAKING SAME Immuno-RX, Inc. (US) 2004-10-13 EP claimed
CN-1450914-A Preparation of clear aqueous solution dosage form containing bile acid SEO-HONG YOO (US) 2003-10-22 CN claimed
US-20030186933-A1 Preparation of aqueous clear solution dosage forms with bile acids YOO SEO HONG (US) 2003-10-02 US claimed
WO-2003049670-A2 ADJUVANT FORMULATIONS FOR BACTERIAL AND VIRUS VACCINES AND METHOD OF MAKING SAME IMMUNO-RX, INC. (US) 2003-06-19 WO claimed
EP-1255566-A2 PREPARATION OF AQUEOUS CLEAR SOLUTION DOSAGE FORMS WITH BILE ACIDS Yoo, Seo Hong (US) 2002-11-13 EP claimed
US-20020031558-A1 Preparation of aqueous clear solution dosage forms with bile acids YOO SEO HONG (US) 2002-03-14 US claimed
WO-2001056547-A2 PREPARATION OF AQUEOUS CLEAR SOLUTION DOSAGE FORMS WITH BILE ACIDS YOO SEO HONG (US) 2001-08-09 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186933-A1 Preparation of aqueous clear solution dosage forms with bile acids SLC10A2, ABCB11, SLC10A1 DNPH1 3446/4885P2RY1 731/4885TAS1R3 596/4885
US-20050148538-A1 Adjuvant formulations for bacterial and virus vaccines and method of making same ITPA, IMPA1, STING1 DNPH1 1087/4885P2RY1 539/4885TAS1R3 4401/4885
US-20070082863-A1 Methods and compositions for maturing dendritic cells utilizing inosine-containing compounds INMT, STING1, ITPA DNPH1 1170/4885P2RY1 456/4885TAS1R3 3353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.